Interactive Savings Map - Find out how much your state saved from generic and biosimilar medicines.

AAM Statement on FTC Report on Patent Settlements

WASHINGTON, DC (May 23, 2019) — By FTC’s own account, current law is working and reverse payment settlements are no longer a systemic problem. Current “pay-for-delay” legislation, however, would unfortunately overturn the Actavis decision and unwind the many pro-competitive benefits that lower prescription drug costs for patients. We urge policymakers to revisit the need for legislation given this new report from the FTC.

Read FTC Report



Rachel Schwartz


About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending. 

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.